Iovance COO has 7,813 RSUs vest into shares

IOVA’s chief operating officer had RSUs vest into common stock, with a portion of the shares withheld to cover tax obligations rather than sold on the market.

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Operating Officer Igor Bilinsky had restricted stock units vest on September 8, 2026, resulting in the acquisition of 7,813 shares of common stock. These shares came from RSUs converting into common stock at no cash exercise price, with each RSU representing one share. Of the vested shares, 3,976 shares of common stock were withheld by the company at a price of $8.70 per share to satisfy mandatory tax withholding obligations, and this was explicitly stated not to be an open market sale. After this vesting event, 46,878 RSUs from the March 5, 2025 grant remain outstanding and will vest in equal quarterly installments, and no transactions were reported as made under a Rule 10b5-1 trading plan.

Insider Trade Summary

7,813 shares exercised/converted

Exercise 3 txns

Insider BILINSKY IGOR

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F4, F5, F6	7,813	$0.00	$0.00
Exercise	Common Stock F1	7,813	$0.00	$0.00
Tax Withholding	Common Stock F2, F3	3,976	$8.70	$35K

Holdings After Transaction: Restricted Stock Units — 46,878 contracts (Direct); Common Stock — 142,074 shares (Direct)

Footnotes (6)

1. F1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. F2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. F3. Represents common stock remaining after deducting the common stock withheld for taxes.
4. F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. F5. The remaining RSUs will vest in equal quarterly installments.
6. F6. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

Key Figures

RSUs vested: 7,813 units Common stock acquired from RSUs: 7,813 shares Shares withheld for taxes: 3,976 shares +2 more

5 metrics

RSUs vested 7,813 units Restricted stock units vested on September 8, 2026

Common stock acquired from RSUs 7,813 shares Shares of Iovance common stock received upon RSU vesting

Shares withheld for taxes 3,976 shares Common stock withheld to satisfy tax withholding on RSU vesting

Tax withholding price $8.70 per share Value applied to common stock withheld for tax obligations

Remaining RSUs from March 5, 2025 grant 46,878 units Unvested RSUs that will vest in equal quarterly installments

Key Terms

Restricted Stock Units, mandatory tax withholding requirements, Rule 10b5-1

3 terms

Restricted Stock Units financial

"Represents such shares underlying the restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding requirements financial

"to satisfy the mandatory tax withholding requirements upon vesting"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for these transactions"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IOVA’s COO Igor Bilinsky report on this Form 4?

He reported the vesting and conversion of 7,813 RSUs into common stock on September 8, 2026, and the related withholding of 3,976 shares to cover tax obligations. The transactions reflect equity compensation events, not open market buying or selling.

How many IOVA shares vested for the COO in this Form 4?

On September 8, 2026, 7,813 restricted stock units vested for IOVA’s chief operating officer, each RSU converting into one share of Iovance Biotherapeutics common stock as part of his equity compensation.

How many IOVA shares were withheld for taxes and at what price?

The company withheld 3,976 shares of IOVA common stock at $8.70 per share to satisfy mandatory tax withholding requirements tied to the RSU vesting. The filing states this was not an open market sale of securities.

How many RSUs does the IOVA COO still hold from the March 5, 2025 grant?

Following this vesting event, 46,878 restricted stock units from the March 5, 2025 grant remain. The filing notes these remaining RSUs will vest in equal quarterly installments going forward.

Were the IOVA Form 4 transactions under a Rule 10b5-1 trading plan?

No. The Form 4 indicates no Rule 10b5-1 trading plan for these transactions, and the tax-related disposition is described as shares withheld by the issuer, not market trades executed under a plan.

Did the IOVA COO sell any shares on the open market in this Form 4?

The filing states that shares were withheld to satisfy tax withholding upon RSU vesting and that this is not an open market sale. It reports no open market sale transactions for the chief operating officer in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 05:01 PM Accepted by SEC EDGAR 09/10/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BILINSKY IGOR

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	09/08/2026		M		7,813	A	$0	146,050	D
Common Stock(2)	09/08/2026		F		3,976	D	$8.7	142,074(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	09/08/2026		M			7,813	(5)	(5)	Common stock	7,813	$0.00	46,878(6)	D

Explanation of Responses:

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.

2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

3. Represents common stock remaining after deducting the common stock withheld for taxes.

4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The remaining RSUs will vest in equal quarterly installments.

6. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

	/s/ Igor Bilinsky	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)